ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial evaluated bromelain, a digestive enzyme supplement, as a possible add-on therapy for mild–moderate ulcerative colitis and measured both clinical scores and inflammatory/biomarker outcomes. Patients interested in nonstandard supplements or in trials for new IBD therapies may find this relevant.
Who Should Pay Attention
Adults with ulcerative colitis, clinicians caring for UC patients, and researchers interested in supplement-based interventions, diet-plus-supplement trials, or biomarker outcomes in IBD.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2, Phase 3
Enrollment52 participants
Study statusCompleted
Source depthTrial registry record
What To Know
This is a completed randomized interventional Phase 2/3 trial registered on ClinicalTrials.gov testing oral bromelain (1,500 mg/day) versus placebo taken for 8 weeks in adults with active mild–moderate ulcerative colitis; participants also followed a low-FODMAP diet during the study.
The study measured symptom scores (SCCAI), IBDQ, blood CRP, total antioxidant capacity (TAC), and TNF-α before and after treatment. Planned enrollment was 52 and the trial location was Tehran, Iran. The record lists inclusion/exclusion criteria, age range (18–70), and that some participants could have concomitant primary sclerosing cholangitis (PSC).
The registry status is marked COMPLETED, but the provided record does not include published results or outcome data in the text shown here. If you are considering supplements or changes to your treatment, discuss them with your gastroenterologist because this registry entry does not replace clinical guidance and does not provide safety or efficacy results.
Keep In Mind
This is a ClinicalTrials.gov record (Phase 2/3, completed) and the extracted text does not present trial results or peer-reviewed publication details. Treat registry entries as study records rather than evidence of benefit; look for a linked publication or contact the investigators for outcome data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorNational Nutrition and Food Technology Institute
Trial IDNCT06351696
Study typeInterventional
Trial phasePhase 2, Phase 3
Enrollment52 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 27, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...
Aquamin® as an Adjuvant Intervention for Ulcerative Colitis
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.